Case Reports in Ophthalmological Medicine · 2013 · 46 citations · 5 references
MedicineDermatologyOphthalmologyChemotherapyMetastasisOcular OncologyMelanocytic LesionsMelanocytic TumorsMelanoma PharmacotherapyOcular TumorsRetinal PharmacotherapyRetinal Pigment EpitheliumBlood - Retinal BarrierBlood-retinal Barrier DysfunctionMapk SignalingMek InhibitionMek InhibitorsMek SignalingMitogen-activated Protein Kinase KinaseMitogen-activated Protein Kinase Pathways
Newer chemotherapeutic agents target extracellular signaling, including the mitogen-activated protein kinase kinase (MEK) pathway. We present a case of a 54-year-old female who developed bilateral multifocal central serous-like chorioretinopathy shortly after starting MEK inhibition for metastatic cutaneous melanoma. There was a complete resolution of findings after drug stoppage. After resuming a lower dose of the MEK inhibitor, the findings recurred again but resolved after drug stoppage. Other etiologies were unlikely given the clinical course. The presumed mechanism involves toxicity to the retinal pigment epithelium, with breakdown of the blood-retinal barrier. Recognition of this side effect is important with this new class of chemotherapy.
5
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty, J. Infante, Adil Daud et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text
Medicine, Oncology, Pharmacology +16
Wenhu Huang, Amy H. Yang, Diane Matsumoto et al. · Journal of Ocular Pharmacology and Therapeutics · 2009 · 93 citations